Drug Trial Radar · NCT01659502
Investigator's Initiated Phase II Study for Pancreatic Cancer Patients
Last checked: Nov 19, 2026Latest source record: Dec 5, 2013 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
10
Planned (sponsor's estimate)
Start
Dec 2013
Primary completion
Oct 2014
Sponsor
- Lead sponsor
- Tiltan Pharma Ltd.Industry
- Sponsor type
- Industry
- First posted
- Aug 7, 2012
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to evaluate the efficacy, safety and tolerability of TL-118 alone or in combination with pancreatic cancer chemotherapy.
Conditions
- Pancreatic Cancer
Interventions
TL-118Drug
TL-118 investigational product is supplied as an oral liquid for daily administration at a specific dosing regimen. Treatment protocol includes weekly therapy cycles
Primary outcomes
What the sponsor says the trial is designed to measure.
- Clinical Benefit MeasurementTime frame: Baseline up to 2 years
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Hadassah Medical Center
Jerusalem, Israel
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.